The Medical Innovation Investment Conference was held in Nanning. Hong Kong Exchanges and Clearing Limited: Hong Kong is once again becoming the preferred listing destination for biotechnology companies.

The 10th China Meheco Group Innovation and Investment Conference, jointly organized by HKEX (00388) and China Meheco Group, was successfully held in Nanjing from October 26th to October 27th. The conference brought together representatives from various domestic and international institutions and government departments. They had in-depth discussions on pharmaceutical research and development achievements, as well as investment trends, and collectively looked forward to the development prospects of China Meheco Group's industry. Charles Li, CEO of HKEX Group, delivered a speech at the opening ceremony, emphasizing the important role of capital markets in accelerating the globalization of innovative pharmaceutical companies in China. HKEX has been committed to building an efficient and diverse international financing platform to inject capital momentum into the development of Chinese biotech companies. This year, IPO financing in the healthcare sector in the Hong Kong market has been particularly active, ranking first globally in terms of funds raised by new listings. Simon Cheung, Head of Listing, Asia at HKEX, pointed out during the forum that HKEX continues to play an important role in assisting global biotech companies with IPO financing. He stated that Hong Kong's healthcare financing market has recently shown impressive performance, thanks to the continuous optimization of regulatory systems, the continuous listing of high-quality innovative enterprises, and the active participation of investors, these three interrelated factors. By 2025, the market has clearly rebounded, and Hong Kong has once again become the preferred listing destination for biotech companies. Up to now, Hong Kong has completed 12 biotech IPOs, raising a total of USD 1.3 billion, ranking first globally in funds raised. At the same time, the secondary financing transactions in the biotech sector are also very active, with a total of USD 4.1 billion raised since the beginning of the year. This reflects gradual recovery of market confidence and also demonstrates the gradual effectiveness of national policy support and capital market reform.